Login to Your Account



Gilead, Janssen showcase HIV advances at CROI

By Michael Fitzhugh
Staff Writer

Tuesday, February 14, 2017

Gilead Sciences Inc., pressured by declining sales in its hepatitis C franchise and slower than anticipated growth in its HIV line-up, is putting its best foot forward at the Conference on Retroviruses and Opportunistic Infections in Seattle this week.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription